WO2007037849A3 - Compositions and methods for the intraocular transport of therapeutic agents - Google Patents

Compositions and methods for the intraocular transport of therapeutic agents Download PDF

Info

Publication number
WO2007037849A3
WO2007037849A3 PCT/US2006/032765 US2006032765W WO2007037849A3 WO 2007037849 A3 WO2007037849 A3 WO 2007037849A3 US 2006032765 W US2006032765 W US 2006032765W WO 2007037849 A3 WO2007037849 A3 WO 2007037849A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
therapeutic agents
intraocular
compositions
transport
Prior art date
Application number
PCT/US2006/032765
Other languages
French (fr)
Other versions
WO2007037849A2 (en
Inventor
Patrick M Hughes
Orest Olejnik
Joan-En Chang-Lin
Original Assignee
Allergan Inc
Patrick M Hughes
Orest Olejnik
Joan-En Chang-Lin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, Patrick M Hughes, Orest Olejnik, Joan-En Chang-Lin filed Critical Allergan Inc
Priority to AU2006295305A priority Critical patent/AU2006295305B2/en
Priority to BRPI0616041-7A priority patent/BRPI0616041A2/en
Priority to JP2008531128A priority patent/JP5122460B2/en
Priority to CA002602440A priority patent/CA2602440A1/en
Priority to EP06802088A priority patent/EP1924292A2/en
Publication of WO2007037849A2 publication Critical patent/WO2007037849A2/en
Publication of WO2007037849A3 publication Critical patent/WO2007037849A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Abstract

Membrane transporter-targeted therapeutic agents and methods of making and using the same.
PCT/US2006/032765 2005-09-16 2006-08-23 Compositions and methods for the intraocular transport of therapeutic agents WO2007037849A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2006295305A AU2006295305B2 (en) 2005-09-16 2006-08-23 Compositions and methods for the intraocular transport of therapeutic agents
BRPI0616041-7A BRPI0616041A2 (en) 2005-09-16 2006-08-23 compositions and methods for intraocular transport of therapeutic agents
JP2008531128A JP5122460B2 (en) 2005-09-16 2006-08-23 Compositions and methods for intraocular delivery of therapeutic agents
CA002602440A CA2602440A1 (en) 2005-09-16 2006-08-23 Compositions and methods for the intraocular transport of therapeutic agents
EP06802088A EP1924292A2 (en) 2005-09-16 2006-08-23 Compositions and methods for the intraocular transport of therapeutic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71794605P 2005-09-16 2005-09-16
US60/717,946 2005-09-16

Publications (2)

Publication Number Publication Date
WO2007037849A2 WO2007037849A2 (en) 2007-04-05
WO2007037849A3 true WO2007037849A3 (en) 2008-01-24

Family

ID=37668145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/032765 WO2007037849A2 (en) 2005-09-16 2006-08-23 Compositions and methods for the intraocular transport of therapeutic agents

Country Status (7)

Country Link
US (2) US7714024B2 (en)
EP (1) EP1924292A2 (en)
JP (2) JP5122460B2 (en)
AU (1) AU2006295305B2 (en)
BR (1) BRPI0616041A2 (en)
CA (2) CA2602440A1 (en)
WO (1) WO2007037849A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
US20070160622A1 (en) * 2005-12-07 2007-07-12 Medivas, Llc Method for assembling a polymer-biologic delivery composition
BRPI0510485A (en) 2004-04-30 2007-11-13 Allergan Inc biodegradable intravitreal tyrosine kinase inhibitor implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8455656B2 (en) * 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
ES2532912T3 (en) 2005-06-01 2015-04-01 Edison Pharmaceuticals, Inc. Active redox therapeutic compounds for the treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
CA2602440A1 (en) * 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
WO2007038246A2 (en) * 2005-09-22 2007-04-05 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
WO2007035938A2 (en) 2005-09-22 2007-03-29 Medivas, Llc BIS-(α-AMINO)-DIOL-DIESTER-CONTAINING POLY(ESTER AMIDE) AND POLY(ESTER URETHANE) COMPOSITIONS AND METHODS OF USE
WO2007100652A2 (en) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
JP5445130B2 (en) * 2006-05-02 2014-03-19 メディバス エルエルシー Delivery of ophthalmic drugs to the exterior or interior of the eye
WO2007133616A2 (en) * 2006-05-09 2007-11-22 Medivas, Llc Biodegradable water soluble polymers
WO2008133021A1 (en) * 2007-04-12 2008-11-06 R-Tech Ueno, Ltd. COMPOSITION FOR AMELIORATING OPTIC NERVE DISORDER COMPRISING PROSTAGLANDIN F2α COMPOUND AS ACTIVE INGREDIENT
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
CA2709412A1 (en) * 2007-07-24 2009-01-29 Medivas, Llc Biodegradable cationic polymer gene transfer compositions and methods of use
ES2600469T3 (en) * 2008-05-23 2017-02-09 National Jewish Health A compound for use in the treatment of lesions associated with exposure to phosgene gas or chlorine gas
JP2012500207A (en) * 2008-08-13 2012-01-05 メディバス エルエルシー AABB-poly (depsipeptide) biodegradable polymer and method of use
MX2011002318A (en) 2008-09-10 2011-05-10 Edison Pharmaceuticals Inc Treatment of pervasive developmental disorders with redox-active therapeutics.
WO2010065649A1 (en) * 2008-12-02 2010-06-10 Allergan, Inc. Injection device
JP2012525399A (en) 2009-04-28 2012-10-22 エジソン ファーマシューティカルズ， インコーポレイテッド Treatment of Leber hereditary optic neuropathy and dominant hereditary optic atrophy using tocotrienol quinone
CN102724951A (en) 2009-11-09 2012-10-10 阿勒根公司 Compositions and methods for stimulating hair growth
EP2563352A4 (en) * 2010-04-27 2013-11-13 Edison Pharmaceuticals Inc Formulations of quinones for the treatment of ophthalmic diseases
CN103459368B (en) * 2011-02-14 2016-06-08 阿勒根公司 The ester derivant of bimatoprost compositions and method
CN103748139B (en) 2011-06-23 2016-08-17 帝斯曼知识产权资产管理有限公司 For delivering the micron particle comprising biodegradable polyester-amide copolymer or the nano-particle of bioactivator
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US20130190324A1 (en) * 2011-12-23 2013-07-25 The Regents Of The University Of Colorado, A Body Corporate Topical ocular drug delivery
EP2844268A4 (en) * 2012-04-20 2015-11-25 Univ Howard Method of treating an ocular disease and compositions effective for treating an ocular disease
CA2901280A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
CN106061490A (en) 2013-10-09 2016-10-26 列奥尼达斯·A·约翰逊 Methods and compositions for treating and preventing signs or symptoms of eye disease
WO2015060812A1 (en) * 2013-10-21 2015-04-30 Howard University Treating ocular disease with efflux transporter inhibitors
PT3351239T (en) 2013-10-31 2020-07-03 Allergan Inc Prostamide-containing intraocular implants and methods of use thereof
CN107106509B (en) 2014-12-18 2021-11-30 帝斯曼知识产权资产管理有限公司 Drug delivery system for delivering acid sensitive drugs
WO2016109457A1 (en) * 2014-12-29 2016-07-07 Orange County Glaucoma Compositions and methods for treating glaucoma
KR101723168B1 (en) * 2015-04-28 2017-04-05 주식회사 대웅 Medium Composition for Preparing Botulinum Toxin
CN113024369A (en) 2015-12-17 2021-06-25 Ptc医疗公司 Compounds for the treatment of oxidative stress disorders
US20230277521A1 (en) * 2022-03-07 2023-09-07 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048190A2 (en) * 2001-12-04 2003-06-12 The Curators Of The University Of Missouri Acyclovir-peptide analogs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6294563B1 (en) * 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
DE60114229T2 (en) * 2000-11-29 2006-07-06 Allergan, Inc., Irvine PREVENTING TRANSPLANT DISCHARGE IN THE EYE
EP1418903A2 (en) * 2001-04-23 2004-05-19 The Board of Regents of the University of Texas System Prostanoids augment ocular drug penetration
CN1313155C (en) 2002-03-18 2007-05-02 诺瓦提斯公司 Topical composition comprising a cyclofructan, a carrier and a drug
JP2004279509A (en) * 2003-03-13 2004-10-07 Toyota Motor Corp Method and system for advertisement distribution, center, and advertisement display device
KR101091461B1 (en) * 2003-11-07 2011-12-07 센주 세이야꾸 가부시키가이샤 Pharmaceutical composition containing prostaglandin
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
CA2602440A1 (en) 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048190A2 (en) * 2001-12-04 2003-06-12 The Curators Of The University Of Missouri Acyclovir-peptide analogs
US20050043246A1 (en) * 2001-12-04 2005-02-24 The Curators Of The University Of Missouri Acyclovir-peptide analogs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CUNHA-VAZ J G: "The blood-ocular barriers: past, present, and future.", DOCUMENTA OPHTHALMOLOGICA. ADVANCES IN OPHTHALMOLOGY 1997, vol. 93, no. 1-2, 1997, pages 149 - 157, XP002447887, ISSN: 0012-4486 *
DUYVURI S ET AL: "Drug delivery to the retina: challenges and opportunities", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 1, 2003, pages 46 - 56, XP008082736, ISSN: 1471-2598 *
HAN ET AL: "Regulation of aquaporin-4 water channels by phorbol ester-dependent protein phosphorylation", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 273, no. 11, 1998, pages 6001 - 6004, XP002147114, ISSN: 0021-9258 *
KIM IN-BEOM ET AL: "Immunocytochemical localization of Aquaporin 1 in the rat retina", NEUROSCIENCE LETTERS, vol. 244, no. 1, 6 March 1998 (1998-03-06), pages 52 - 54, XP002447954, ISSN: 0304-3940 *

Also Published As

Publication number Publication date
JP5122460B2 (en) 2013-01-16
AU2006295305A1 (en) 2007-04-05
CA2602440A1 (en) 2007-04-05
AU2006295305B2 (en) 2013-01-31
US7714024B2 (en) 2010-05-11
BRPI0616041A2 (en) 2011-06-07
JP5567082B2 (en) 2014-08-06
US20070066541A1 (en) 2007-03-22
CA2850858A1 (en) 2007-04-05
JP2009508857A (en) 2009-03-05
EP1924292A2 (en) 2008-05-28
WO2007037849A2 (en) 2007-04-05
US20100222587A1 (en) 2010-09-02
JP2013014600A (en) 2013-01-24
US8637571B2 (en) 2014-01-28

Similar Documents

Publication Publication Date Title
WO2007037849A3 (en) Compositions and methods for the intraocular transport of therapeutic agents
WO2008034013A3 (en) Medical devices and methods of making the same
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
WO2008052187A3 (en) Antibodies and immunoconjugates and uses therefor
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
WO2007127834A3 (en) Compositions and methods of preparation thereof
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2007140371A8 (en) Antibodies and immunoconjugates and uses therefor
WO2007044026A3 (en) Compositions comprising modified collagen and uses therefore
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
WO2006127768A3 (en) Microscale micropatterned engineered in vitor tissue
WO2008121767A3 (en) Stitched polypeptides
WO2005110396A3 (en) Nitrated lipids and methods of making and using thereof
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
EP1971372A4 (en) Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
WO2006115847A3 (en) Coated endoprostheses
WO2006119329A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2006026759A3 (en) Humanized anti-beta7 antagonists and uses therefor
WO2006133271A3 (en) Compositions and methods relating to target-specific photodynamic therapy
WO2008027600A3 (en) Imatinib compositions
WO2007075987A3 (en) Active surface coupled polymerases
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof
WO2005108428A3 (en) Cd40 splice variants and their uses
WO2007127506A3 (en) Anti-ephrinb2 antibodies and methods using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2602440

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006295305

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006295305

Country of ref document: AU

Date of ref document: 20060823

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006802088

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008531128

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: PI0616041

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080314